15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Tenax Therapeutics Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $27.00 to $50.00, a moderate spread. The average target of $38.20 sits 142% above the current $15.79. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.37 next quarter toward $-1.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Tenax Therapeutics Inc.
As of Jul, 5 of 5 firms rate TENX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TENX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.37
Range $-0.44 – $-0.27 · 6 analysts · -8% YoY
Next period, 6 analysts expect Tenax Therapeutics Inc to earn $-0.37 a share (range $-0.44 – $-0.27), versus $-0.40 a year earlier. Full-year consensus is $-1.40, growing to $-1.38 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Tenax Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TENX.
#1
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$50.00+216.8% to target
Overall win rate
34%
+ Follow
#2
Seamus Fernandez
Guggenheim
Buy
$40.00+153.4% to target
Coverage
—
+ Follow
#3
David Risinger
Leerink Partners
Buy
No targeton TENX
Coverage
—
+ Follow
#4
OB
Olivia Brayer Saunders
Cantor Fitzgerald
Buy
$35.00+121.7% to target
Coverage
—
+ Follow
#5
MP
Matt Phipps
William Blair
Buy
No targeton TENX
Coverage
—
+ Follow
TENX stock forecast FAQ
What is TENX's average 12-month price target?+
The 5 analysts with a live target average $38.20 for Tenax Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $27.00 low.
Is TENX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TENX?+
The Street-high target is $50.00 (Piper Sandler), and the Street-low is $27.00 (Chardan Capital). The average of all 5 active targets is $38.20.
How many Wall Street analysts cover TENX?+
5 analysts have an active rating on Tenax Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering TENX?+
Among analysts who currently cover TENX, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #152). Their current call is Buy with a $50.00 target.
What is Tenax Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.37 per share (range $-0.44 – $-0.27) across 6 analysts. Full-year EPS is projected at $-1.40, rising to $-1.38 the following year.
How much revenue is Tenax Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TENX lately?+
As of Jul, 5 of 5 firms rate TENX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TENX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Chardan Capital
